Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.88 -0.03 (-0.12%)
Streaming Delayed Price Updated: 10:33 AM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
From Pacira BioSciences
Via GlobeNewswire
News headline image
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
From SkyMedia, LLC
Via GlobeNewswire
News headline image
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗
The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility. 
Via Talk Markets
Topics Stocks / Equities
News headline image
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
PCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
PCRX STOCKHOLDERS: Contact Robbins LLP for Information About the Pacira BioSciences, Inc. Class Action Before the Expiration of the Lead Plaintiff Deadline
From Robbins LLP
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
From Pacira BioSciences
Via GlobeNewswire
News headline image
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals. ↗
PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate ↗
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery. 
Via Benzinga
News headline image
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.